Actively Recruiting
Study of ARD001 for Safety and Tolerability in Healthy Men and Adults With Hemophilia A Using Single and Multiple Doses
Led by Arditus Pte Ltd · Updated on 2026-10-28
20
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating ARD001, an investigational medicine for treating hemophilia A. The study includes a Phase 1 trial with healthy adult volunteers aged 21 to 45 years who receive a single dose of ARD001 or placebo to assess safety, tolerability, how the drug moves through the body, its effects on blood clotting, and whether the body produces antibodies against the drug. If Phase 1 results are positive and approvals are obtained, Phase 2 will test repeated doses in adults with hemophilia A. In Phase 1, participants are randomly assigned to receive a single subcutaneous dose of ARD001 at one of three increasing dose levels 0.01, 0.1, or 0.3 mgkg or a matching placebo. Phase 2 will involve multiple doses of ARD001 in adults with hemophilia A, with dosing details to be defined later. Phase 1 placebo participants only receive a single dose no placebo is planned for Phase 2. Participants will undergo medical evaluations including physical exams, vital signs, ECGs, and laboratory tests to monitor safety and drug effects through Days 29 to 113 depending on dose group. Researchers will measure adverse events, changes in blood chemistry, coagulation parameters, antibody development, and drug levels in the blood. The study aims to identify safe doses and understand drug behavior to guide further development, with participation lasting up to several months for follow-up assessments.
CONDITIONS
Brief Title
A First-in Human Study of ARD001 in Healthy Volunteers and People With Hemophilia A
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here